Zibotentan for the treatment of castrate-resistant prostate cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 7, 2010, Pages 899-908

  Shepard, Dale R ^a   Dreicer, Robert ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Castrate resistant prostate cancer; Endothelin receptor; Endothelin 1; Zibotentan

Indexed keywords

ANTIANDROGEN; ATRASENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; DOCETAXEL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ITRACONAZOLE; MITOXANTRONE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; PAMIDRONIC ACID; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RIFAMPICIN;

AREA UNDER THE CURVE; BINDING AFFINITY; BONE METASTASIS; BRAIN HEMORRHAGE; CANCER CELL; CANCER PAIN; CELL GROWTH; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; HEADACHE; HEART FAILURE; HUMAN; MALE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NONHUMAN; NOSE CONGESTION; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGNOSIS; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG EVALUATION, PRECLINICAL; ENDOTHELIN-1; HUMANS; MALE; MOLECULAR STRUCTURE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTOR, ENDOTHELIN A;

EID: 77953388023     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.491822     Document Type: Review

References (63)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249
2. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-245
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-1520
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512
5. Warren R, Liu G. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs 2008;17(8):1237-1245
6. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248(5 Pt 1):C550-6
7. Levin ER. Endothelins. N Engl J Med 1995;333(6):356-363
8. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411-415
9. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86(8):2863-2867
10. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 1998;9(9):378-383
11. Bagnato A, Tecce R, Di Castro V, Catt KJ. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res 1997;57(7):1306-1311
12. Douglas SA, Ohlstein EH. Signal transduction mechanisms mediating the vascular actions of endothelin. J Vasc Res 1997;34(3):152-164
13. Wu-Wong JR, Chiou WJ, Wang J. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J Pharmacol Exp Ther 2000;293(2):514-521
14. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992;13(3):103-108
15. Bagnato A, Tecce R, Moretti C, et al. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res 1995;1(9):1059-1066
16. Battistini B, Chailler P, D'Orleans-Juste P, et al. Growth regulatory properties of endothelins. Peptides 1993;14(2):385-399
17. Shichiri M, Hirata Y, Nakajima T, et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 1991;87(5):1867-1871
18. Khodorova A, Montmayeur JP, Strichartz G. Endothelin receptors and pain. J Pain 2009;10(1):4-28
19. Raffa RB, Schupsky JJ, Jacoby HI. Endothelin-induced nociception in mice: mediation by ETA and ETB receptors. J Pharmacol Exp Ther 1996;276(2):647-651
20. Yuyama H, Koakutsu A, Fujiyasu N, et al. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 2004;44(Suppl 1):S479-82
21. Yuyama H, Koakutsu A, Fujiyasu N, et al. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol 2004;492(2-3):177-182
22. Curtis N, Howard Z, Brooks N, Curwen J. ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects (abstract 78). Eur J Cancer Suppl 2004;2:27
23. Curwen JO, Wilson C. ZD4054: a specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease (abstract 340). Eur J Cancer 2002;7(Suppl 7):S102
24. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199(3):1461-1465
25. Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001;165(3):1033-1036
26. Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 2009;20(2):83-88
27. Kobayashi S, Tang R, Wang B, et al. Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol Pharmacol 1994;45(2):306-311
28. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56(4):663-668
29. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53(5):1063-1069
30. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276(2):473-481
31. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944-949
32. Rosenblatt R, Valdman A, Cheng L, et al. Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia. Anal Quant Cytol Histol 2009;31(3):137-142
33. Russell JS, Chi H, Ward PE. Endothelin-1 metabolism by neutral endopeptidase-24.11 identified in cultured human skeletal muscle myocytes and fibroblasts. Immunopharmacology 1996;32(1-3):180-182 (Pubitemid 26197997)
34. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent Progression. Nat Med 1998;4(1):50-57
35. Langenstroer P, Tang R, Shapiro E, et al. Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol 1993;150(2 Pt 1):495-499
36. Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000;83(3):360-365
37. DePuy V, Anstrom KJ, Castel LD, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007;15(7):869-876
38. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14(5):317-322
39. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16(4):579-584
40. Kasperk CH, Borcsok I, Schairer HU, et al. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int 1997;60(4):368-374
41. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003;100(19):10954-10959
42. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-689
43. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110(9):1959-1966
44. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008;113(9):2478-2487
45. Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005;92(12):2148-2152
46. Dreicer R, Curtis N, Morris C, et al. ZD4054 specifically inhibits endothelin A receptor-mediated effects, but not endothelin B receptor-mediated effects (abstract 237). Proceedings of the ASCO Multidisciplinary Prostate Cancer Symposium; 17-19 February 2005, Orlando, USA
47. Swaisland HC, Oliver SD, Morris T, et al. In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers. Xenobiotica 2009;39(6):444-456
48. Clarkson-Jones J, Kenyon A, Kemp J, et al. Metabolism of [14C]-ZD4054 in healthy volunteers (abstract 724). Eur J Cancer Suppl 2007;5(4):114
49. Williams ED, Thompson EW, Sreedharan D, Brooks N. The combination of a specific endothelin A receptor antagonist ZD4054 and a submaximal bisphosphonate pamidronate prevents bone metastasis. Eur J Cancer Suppl 2006;4:15
50. Schelman WR, Liu G, Wilding G, et al. A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 2009. [Epub ahead of print]
51. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55(5):1112-1123
52. James ND, Morris T, Phung D, et al. Phase II trial of the specific endothelin A receptor antagonist zibotentan (ZD4054) in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases: final analysis of safety and efficacy (abstract P-7013). Eur J Cancer Suppl 2009;7:410
53. Dawson N, Payne H, Battersby C, et al. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054). J Cancer Res Clin Oncol 2010. [Epub ahead of print]
54. Fizazi K, Miller K. Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer. BJU Int 2009;104(10):1423-1425
55. A phase III trial of ZD4054 (endothelin A antagonist) in non-metastatic hormone resistant prostate cancer (ENTHUSE M0). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00626548.[Last accessed 17 May 2010]
56. A phase III trial of ZD4054 (endothelin A antagonist) in hormone resistant prostate cancer with bone metastases (ENTHUSE M1). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00554229. [Last accessed 17 May 2010]
57. A phase III trial of ZD4054 (endothelin A antagonist) and docetaxel in metastatic hormone resistant prostate cancer (ENTHUSEM1C). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00617669.[Last accessed 17 May 2010]
58. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28(9):1496-1501
59. Higano CS, Schellhammer PF, Small EJ,et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115(16):3670-3679
60. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC) (abstract 8). Proceedings of the ASCO Genitourinary Cancers Symposium; 5-7 March 2010, San Francisco, USA
61. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28(9):1489-1495
62. Sartor AO, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) (abstract 9). Proceedings of the ASCO Genitourinary Cancers Symposium; 5-7 March 2010, San Francisco, USA
63. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis 2009;12(3):241-246